Lupin is India's most reputed pharma brand

Image
IANS Hyderabad
Last Updated : Aug 17 2016 | 6:57 PM IST

Mumbai-based Lupin Pharmaceuticals is India's most reputed pharmaceutical brand, said a report by Bluebytes, a leading media-analytics company on Wednesday.

Sun Pharma is the second most reputed brand while Cipla is at third position. Hyderabad-based Dr Reddy's Laboratories stands at fourth, according to a statemet from Bluebytes.

Eight Hyderabad-based brands have made it to the list.

Aurobindo Pharma occupies 11th position while Natco Pharma stood at 21st place in the list. Suven Life Sciences ranked at 40, Divis Laboratories at 44th, Zenotech Laboratotries at 48th, Indian Immunologicals at 49th and Biological E. ranked 52nd.

Among global brands GSK leads the way followed by Pfizer. Abbott's ranked India's third most reputed among International brands.

There were 41 domestic and 17 international pharmaceutical brands listed in the study by BlueBytes conducted in association with TRA Research (both part of the Comniscient Group) which released 'India's Most Reputed Pharmaceutical Brands 2016'.

This report is the second in the India's most reputed brands series, and the company is set to launch a report each month covering different sectors. The study evaluates brand's brand reputation by analysing media and consumer perceptions.

"India's reputation as the largest producer of generic drugs in the world has become vulnerable in light of the changing patent regime in the country. Reports say that by 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size," said Pooja Kaura, Chief Spokesperson for India's Most Reputed Brands.

--IANS

ms/lok/vt

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 17 2016 | 6:46 PM IST

Next Story